Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05879744 · ClinicalTrials.gov registry record · Phase 1
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
A Phase 1 study of NHL and NHL, Relapsed, Adult, sponsored by Cullinan Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 6
- Study locations
NCT05879744: Active Phase 1 study of NHL and NHL, Relapsed, Adult, sponsored by Cullinan Therapeutics.
NCT05879744 is a Phase 1 study of NHL and NHL, Relapsed, Adult that is active but no longer recruiting, run by Cullinan Therapeutics. The registered enrollment target is 90 participants, above the 80-participant average among 8 other NHL trials with a reported enrollment target (13% higher). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05879744, a Phase 1 study of NHL and NHL, Relapsed, Adult, is active but no longer recruiting, sponsored by Cullinan Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 6
- Study locations
Study Summary
CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).
Primary Outcome
Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs); incidence of dose interruptions and delays
Conditions Studied
Interventions
- DRUG CLN-978
Study Locations (6)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- City of Hope - Duarte
Georgia
- Winship Cancer Institute at Emory University - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
New Jersey
- Hackensack University Medical Center - Hackensack
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-05-31 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What the registry record for NCT05879744 still lists
NCT05879744 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, above the 80-participant average among 8 other NHL trials with a reported enrollment target (13% higher).
The record links to 2 conditions, with NHL appearing as the primary indexed condition, and to 1 intervention - of which CLN-978 is the first listed.
NCT05879744 lists 6 locations in 6 states (Alabama, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT05879744 about?
NCT05879744 is a clinical study titled "A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)". CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).
What is the current status of trial NCT05879744?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2023-05-31. Estimated completion is 2027-04.
What conditions does trial NCT05879744 study?
This clinical trial studies the following conditions: NHL, NHL, Relapsed, Adult.
What interventions are being tested in trial NCT05879744?
The interventions under investigation include: CLN-978 (DRUG).
Who is sponsoring clinical trial NCT05879744?
This trial is sponsored by Cullinan Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05879744 being conducted?
This trial has 6 study locations across Alabama, California, Georgia, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NHL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05879744's enrollment target sits among peer trials
90 5th of 8 higher than 4 of 8 other NHL trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NHL trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
RECRUITING · Phase 1
-
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
COMPLETED · Phase 1
-
SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors
RECRUITING · NA
-
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI